No, a PSA rise from 0.01 to 0.02 ng/mL does NOT constitute biochemical recurrence
The standard definition of biochemical recurrence after radical prostatectomy requires a PSA ≥0.2 ng/mL, confirmed by a subsequent measurement also showing PSA >0.2 ng/mL. 1 Your patient's PSA of 0.02 ng/mL remains well below this threshold.
Understanding the Standard Definition
The AUA guideline review identified that among 53 different definitions used for biochemical recurrence after radical prostatectomy, PSA >0.2 ng/mL was the most commonly used cutpoint (used in 35 studies), representing the consensus standard 1. This definition balances sensitivity for detecting true recurrence against specificity to avoid false alarms.
The guideline specifically recommends:
- A cutpoint between 0.2 and 0.4 ng/mL is most accurate for defining biochemical recurrence that will ultimately translate into clinical failure
- Any detectable PSA should be repeated for confirmation to eliminate laboratory error
- A washout period of at least 6 weeks post-surgery should occur before obtaining the first PSA 1
Clinical Significance of Your Patient's PSA Level
At 0.02 ng/mL, your patient falls into an important prognostic category:
Patients with PSA <0.02 ng/mL at 5 years post-radical prostatectomy have a 98.5% 10-year biochemical recurrence-free survival rate 2. This recent 2024 study using ultra-sensitive PSA measurements (detection limit 0.01 ng/mL) demonstrated that PSA ≥0.02 ng/mL at 5 years was an independent predictor of late recurrence (HR 37.5, p<0.001), but values below 0.02 ng/mL carried very low risk.
A 2003 study examining ultra-sensitive PSA measurements found that:
- PSA doubling time was 22.4 months for patients whose PSA never exceeded 0.1 ng/mL
- Only when PSA reached >0.1 ng/mL did 75% progress to ≥0.2 ng/mL 3
- PSA values below 0.4 ng/mL "lack sufficient clinical significance" for defining recurrence
What This Means for Management
Continue routine surveillance without intervention. Your patient requires:
- Repeat PSA measurement in 3-6 months to assess trajectory
- Monitor for PSA velocity and doubling time if values continue to rise
- No salvage therapy is indicated until PSA reaches ≥0.2 ng/mL on confirmatory testing
Important caveat: While not meeting criteria for biochemical recurrence, patients with PSA >0.1 ng/mL should be monitored more closely with shorter intervals, as progression to ≥0.2 ng/mL becomes more likely 3. However, at 0.02 ng/mL, your patient hasn't reached even this intermediate threshold.
Common Pitfall to Avoid
Do not confuse "detectable PSA" with "biochemical recurrence." Ultra-sensitive assays can detect PSA at 0.01 ng/mL, but detectability alone does not equal recurrence 2, 3. The 0.2 ng/mL threshold exists precisely because lower values often represent benign residual prostatic tissue rather than cancer recurrence, and many patients with low detectable PSA never progress 4.
A subset of patients (31.3% in one series) with PSA >0.1 ng/mL show no progressive increase over years of follow-up, with median PSA velocity of only 0.034 ng/mL/year 4. This underscores why the higher 0.2 ng/mL threshold is clinically appropriate.